Fresh data sets up showdown for Lilly's Taltz vs Cosentyx

In the highly competitive IL-inhibitor space, securing new indications has been a key strategy for drugmakers looking to gain an edge.

By Jacob Bell • Feb. 14, 2018

Industry touts savings potential of generics and biosimilars

The trade body for generics and biosimilar manufacturers warns of barriers to entry for its products.

By Suzanne Elvidge • Feb. 14, 2018

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

BIO: Pain pipeline lacking as opioid crisis continues

The analysis comes as a new Senate report calls into question drugmaker ties to advocacy groups in fighting the epidemic.

By Suzanne Elvidge • Feb. 14, 2018

New approval helps Vertex's 'cleanest growth story in biotech'

Symdeko, a combination treatment for cystic fibrosis, holds a price tag of $292,000 and could provide Vertex up to $200 million in revenue by year's end.

By Jacob Bell • Feb. 13, 2018

Teva's Copaxone sales hit hastened with OK of Novartis copy

U.S. approval of Novartis' version of Copaxone 40 mg came earlier than Teva had assumed, putting further pressure on the Israeli drugmaker's top seller. 

By Ned Pagliarulo • Feb. 13, 2018

What Gilead taught pharma about pricing a cure

With Sovaldi in the rearview mirror and gene therapies progressing quickly, the industry is debating what lessons can be learned about pricing a cure.

By Lisa LaMotta • Feb. 12, 2018

Maker of Oxycontin to halt opioid promotion to doctors

Purdue Pharma faces sharp criticism, as well as lawsuits, for the role its marketing of prescription painkillers may have played in shaping the opioid epidemic.

By Ned Pagliarulo • Feb. 12, 2018

Gilead HIV triplet wins approval, prompts GSK-backed patent lawsuit

Biktarvy's broad label sets it up to steal market share in the HIV space and become another blockbuster drug in Gilead's arsenal.

By Jacob Bell • Feb. 8, 2018

Pharma wades into the world of virtual reality marketing

The technology offers drugmakers and sales reps an original way to tell stories. But whether it will hold up to the test of time remains to be seen.

By Jacob Bell • Feb. 7, 2018

Express Scripts: Plan drug spending rose at slowest rate in 24 years

The PBM says its efforts to rein in rising drug costs have helped the plans it administers secure hundreds of millions in savings last year.

By Ned Pagliarulo • Feb. 7, 2018

New York latest to sue opioid manufacturer Insys

The New York lawsuit is the latest in a spate against the drug company: North Carolina, New Jersey and Illinois have all engaged in legal action against Insys.

By David Lim • Feb. 5, 2018

Allergan picks up pneumonia indication for Avycaz

It's the first time in more than 15 years the FDA approved a gram-negative antibiotic for hospital and ventilator pneumonia.

By Suzanne Elvidge • Feb. 2, 2018

Pfizer's manufacturing fix clears path for Momenta's Copaxone generic

The big pharma remedied issues at its McPherson plant, meaning the launch of 40 mg Glatopa could come "at any time."

By Jacob Bell • Feb. 1, 2018

FDA adds black box warning to Intercept's Ocaliva

Shares in the New York biotech rose on relief the FDA's caution did not broadly limit use of the drug in patients with mild or moderate liver disease. 

By Ned Pagliarulo • Feb. 1, 2018

Vertex looks to own CF market before shifting focus

The biotech revealed the two triple combo regimens it's taking into Phase 3 as it closes in on serving 90% of the cystic fibrosis market.

By Jacob Bell • Jan. 31, 2018

Boehringer strikes Jardiance outcomes deal with Prime PBM

Intense competition in the diabetes drugs market has pushed manufacturers to search for ways to gain an edge, including value-based deals with payers.

By Jacob Bell • Jan. 31, 2018

FDA turns to drug packaging in bid to combat opioid crisis

The regulator aims to check abuse of Imodium by changing how the drug is packaged, and is considering similar approaches for immediate release opioids.

By Suzanne Elvidge • Jan. 31, 2018

How Amazon, JPM and Berkshire could disrupt healthcare (or not)

"News of three corporate giants forming an independent healthcare company proves every business is a healthcare business," said David Vivero, CEO of digital health startup Amino.

By Shannon Muchmore, Daphne Howland & Jeff Byers • Jan. 31, 2018

State of the Union: 4 things Trump said on healthcare

Most of the healthcare ideas the president put forward have little chance of being enacted, and the industry no longer seems responsive to his comments. 

By David Lim • Jan. 31, 2018

Amazon, JPM, Berkshire form independent health company

The corporate giants gave few details, but said the initial aim is to provide U.S. staff with "high-quality and transparent healthcare at a reasonable cost."

By Shannon Muchmore • Jan. 30, 2018

How Bristol-Myers and Pfizer are using real-world data to unseat warfarin

Eliquis, the pharmas' blood thinner, is now a blockbuster. Yet the companies see more growth ahead, tapping real-world data to convince doctors and payers.

By Ned Pagliarulo • Jan. 29, 2018

When real-world evidence becomes a real headache

After devoting considerable time and resources to find out how a product works in everyday life, drugmakers can be left with more questions than answers.

By Jacob Bell • Jan. 29, 2018

Payers wade into real-world evidence, but tread lightly

Insurers and pharmacy benefit managers are wary about the quality of data underlying real-world evidence.

By David Lim • Jan. 29, 2018

ICER: High-priced Hemlibra could reduce hemophilia costs

Even though the drug's price is high, once-weekly Hemlibra could save costs for the U.S. healthcare system.

By Suzanne Elvidge • Jan. 29, 2018

US in 'desperate need' of biosimilars: Novartis' Narasimhan

Incoming CEO Vas Narasimhan expects significant uptake of biosimilars in the future, despite a sluggish start in the U.S. for the copycat biologics.  

By Ned Pagliarulo • Jan. 24, 2018